Gallo MF et al. Combination contraceptives: effects on weight. Cochrane Database of Systematic Reviews, 2014. DOI: 10.1002/14651858.CD003987.pub5. https://pubmed.ncbi.nlm.nih.gov/24477630/ — Systematischer Review, 49 randomisierte Studien, 85 Gewichtsvergleiche.
Lopez LM et al. Progestin-only contraceptives: effects on weight. Cochrane Database of Systematic Reviews, 2016. DOI: 10.1002/14651858.CD008815.pub4. https://pubmed.ncbi.nlm.nih.gov/27567593/ — Systematischer Review, 22 Studien, 11.450 Frauen.
Beksinska M et al. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial. eClinicalMedicine, 2021;34:100800. DOI: 10.1016/j.eclinm.2021.100800. https://pmc.ncbi.nlm.nih.gov/articles/PMC8056402/ — ECHO, Gewichtsauswertung.
Vickery Z et al. Weight Change at 12 Months in Users of Three Progestin-Only Contraceptive Methods. Contraception, 2013. PMID: 23582238. https://pmc.ncbi.nlm.nih.gov/articles/PMC3951762/ — CHOICE-Unterstudie, 427 Frauen.
Berenson AB, Rahman M. Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. American Journal of Obstetrics and Gynecology, 2009;200(3):329.e1–329.e8. DOI: 10.1016/j.ajog.2008.12.052. https://pmc.ncbi.nlm.nih.gov/articles/PMC2853746/
Le YC et al. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstetrics & Gynecology, 2009;114:279–284. DOI: 10.1097/AOG.0b013e3181af68b2. https://pmc.ncbi.nlm.nih.gov/articles/PMC2727133/
Modesto W et al. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use. European Journal of Contraception & Reproductive Health Care, 2014. DOI: 10.3109/13625187.2014.951433. https://pubmed.ncbi.nlm.nih.gov/25160484/
Bahamondes L et al. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement. Contraception, 2018;98:181–187. DOI: 10.1016/j.contraception.2018.05.009. https://pubmed.ncbi.nlm.nih.gov/29777663/
Dal’Ava N et al. Body weight and composition in users of levonorgestrel-releasing intrauterine system. Contraception, 2012;86:350– 353. DOI: 10.1016/j.contraception.2012.01.017. https://pubmed.ncbi.nlm.nih.gov/22445431/
Changes in Body Composition in Women using Long-acting Reversible Contraception. Contraception, 2017. PMID: 28041992. https://pmc.ncbi.nlm.nih.gov/articles/PMC5376505/ — 149 auswertbare Frauen.
Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. 2010. PMID: 20201608. https://pubmed.ncbi.nlm.nih.gov/20201608/ — 768 randomisierte Frauen, 13 Zyklen.
Lete Lasa I, Novalbos J. Actualización en anticoncepción hormonal combinada por vía oral: 17 beta estradiol y acetato de nomegestrol. Progresos de Obstetricia y Ginecología, 2020;63:235–243. https://sego.es/documentos/progresos/v63-2020/n4/RC-actualizacion-anticoncepcion-hormonal_V02.pdf — Spanische narrative Übersicht, Gewichtsdaten aus Samba und Rumba.
Oral Contraceptive Use, Micronutrient Deficiency, and Obesity among Premenopausal Females in Korea: The Necessity of Dietary Supplements and Food Intake Improvement. 2016. PMID: 27348598. https://pubmed.ncbi.nlm.nih.gov/27348598/ — Koreanische Beobachtungsstudie mit 39.189 Frauen.
Trends and Factors Associated with Oral Contraceptive Use among Korean Women. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8544440/ — Analyse koreanischer Gesundheitsdaten.
Lund M et al. Hormonal Contraception Use and Changes in Body Mass Index: A Cohort Study. BJOG, erstmals online 10. November 2026. DOI: 10.1111/1471-0528.70378. https://pubmed.ncbi.nlm.nih.gov/43008787/ — 47.148 Frauen, Beobachtungsstudie.
Oliveira et al. Subdermal implants vs. levonorgestrel intrauterine devices outcomes in reproductive-aged women: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 2025. DOI: 10.1007/s00404-025-07943-6. https://link.springer.com/article/10.1007/s00404-025-07943-6 — Sechs randomisierte Studien mit 1.503 Frauen.
Lazorwitz A et al. An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users. Contraception, 2020;102:180–185. DOI: 10.1016/j.contraception.2020.05.002. https://pmc.ncbi.nlm.nih.gov/articles/PMC7483263/
レジスタンストレーニング介入後の体組成に対する経口避妊薬の影響:システマティックレビュー [Einfluss oraler Kontrazeptiva auf Körperzusammensetzung nach Krafttraining: systematischer Review]. J-STAGE, 2026;33(3):58–68. DOI: 10.60349/scjj.33.3_58. https://www.jstage.jst.go.jp/article/scjj/33/3/33_58/_article/-char/en
The Effects of Hormonal Contraceptives on Body Weight and Metabolic Parameters: A Meta-Analysis of Randomized Controlled Trials with Non-Hormonal Methods, Placebo, or No Intervention as Controls. Archives of Obesity and Metabolism, 2025. https://koreascience.or.kr/article/JAKO202519050404516.page — Sieben randomisierte Studien, 9.331 Frauen; genaue Skalierung der gepoolten Gewichtseffekte vor grafischer Verwendung prüfen.
Haute Autorité de Santé. Contraception chez la femme adulte et de l’adolescente en âge de procréer. https://www.has-sante.fr/jcms/c_1752542 — Französische nationale klinische Empfehlungen.
Bundesinstitut für Öffentliche Gesundheit. Die Pille – familienplanung.de. https://www.familienplanung.de/verhuetung/verhuetungsmethoden/pille/ — Deutschsprachige öffentliche Gesundheitsinformation.
World Health Organization. Medical eligibility criteria for contraceptive use, sixth edition. Geneva, 2025. ISBN 978-92-4-011558-3. https://www.who.int/publications/i/item/9789240115583/
Faculty of Sexual and Reproductive Healthcare. FSRH CEU Statement: Contraception and Weight Gain. 12. August 2019. https://www.fsrh.org/Public/Public/Documents/fsrh-ceu-statement-contraception-and-weight-gain.aspx
U.S. National Library of Medicine / DailyMed. ZEPBOUND (tirzepatide), aktuelle Verschreibungsinformation, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b — Wechselwirkung mit oralem hormonellem Schutz.
Korea Disease Control and Prevention Agency. 국가건강정보포털: 피임 [Staatliches Gesundheitsportal: Verhütung], Stand 2026. https://health.kdca.go.kr/healthinfo/biz/health/gnrlzHealthInfo/gnrlzHealthInfo/gnrlzHealthInfoView.do?cntnts_sn=6538
Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024; Appendix A. https://www.cdc.gov/contraception/hcp/usspr/classifications-mec-contraception.html
European Medicines Agency. Evra – Arzneimittelinformation und Wirksamkeit bei höherem Gewicht. https://www.ema.europa.eu/en/medicines/human/EPAR/evra
U.S. Food and Drug Administration. TWIRLA (levonorgestrel/ethinylestradiol) transdermal system, Fachinformation 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/204017s009lbl.pdf
Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception, 2012. PMID: 22402256. https://pubmed.ncbi.nlm.nih.gov/22402256/
Family planning and nutrition: systematic review of the effects of family planning on nutritional status of adolescent girls and women of reproductive age. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12184413/
Assurance Maladie. Contraception hormonale : pilule, patch, anneau vaginal, implant, injection intramusculaire. Aktualisierung 10. September 2026. https://www.ameli.fr/assure/sante/themes/contraception/methodes-contraception-hormonale
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Pille & Co.: Hormonelle Verhütung. https://www.gesundheitsinformation.de/pille-co-hormonelle-verhuetung.html
Faculty of Sexual and Reproductive Healthcare. Patient information: GLP-1 agonists and contraception. https://www.fsrh.org/Common/Uploaded%20files/documents/Patient-information-GLP-1-agonists-and-contraception.pdf
Curtis KM, Nguyen AT, Tepper NK et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2024. MMWR Recommendations and Reports 2024;73(RR-3):1–77. DOI: 10.15585/mmwr.rr7303a1. Leitlinie mit Hinweisen zum Gewicht bei DMPA und anderen Verhütungsmitteln. https://www.cdc.gov/mmwr/volumes/73/rr/rr7303a1.htm
American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 602: Depot medroxyprogesterone acetate and bone effects. Obstetrics & Gynecology 2014;123:1398–1402. DOI: 10.1097/01.AOG.0000450758.95422.c8. Knochenmineraldichte unter DMPA und nach Absetzen. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2014/06/depot-medroxyprogesterone-acetate-and-bone-effects
Berenson AB, Rahman M. Volltext und ergänzende Nachbeobachtungsanalysen zu derselben Kohorte wie [S05]: Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. 2009. Kein unabhängiger zweiter Datensatz. https://pmc.ncbi.nlm.nih.gov/articles/PMC2853746/
Society of Family Planning. Clinical Recommendation: Emergency contraception. Contraception 2023. DOI: 10.1016/j.contraception.2023.109958. Vergleich verschiedener Notfallmethoden und Hinweise zum Gewicht. https://doi.org/10.1016/j.contraception.2023.109958
European Medicines Agency. Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women, regardless of bodyweight. Mitteilung 2014. Bewertungen von Daten bei höherem BMI. https://www.ema.europa.eu/en/news/levonorgestrel-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight
Faculty of Sexual and Reproductive Healthcare. FSRH Guideline: Overweight, Obesity and Contraception. 2019. Leitlinienbezogene Empfehlungen zur Notfallverhütung und zu BMI. https://www.cosrh.org/Common/Uploaded%20files/documents/1overweight-obesity-and-contraception-guideline-april-2019.pdf
International PCOS Network. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Human Reproduction 2023;38:1655–1679. Unterscheidung von antiandrogener Symptomtherapie und metabolischer Behandlung. https://pmc.ncbi.nlm.nih.gov/articles/PMC10505534/
Australian Therapeutic Goods Administration. Updated contraception advice for Mounjaro (tirzepatide). Veröffentlichung 1. Dezember 2025. Regulatorischer Hinweis auf mögliche verringerte Wirksamkeit oraler Verhütung. https://www.tga.gov.au/news/safety-updates/updated-contraception-advice-mounjaro-tirzepatide
Kapitel 35 von 35 · Verhütung und Gewicht
Literaturverzeichnis und Quellenregister
41 Quellen zum Ratgeber Verhütung und Gewicht: Cochrane-Reviews, die ECHO-Studie, Leitlinien und Behörden. Jede Quelle mit Link zum Original.
